Radiation therapy has a side effect that oncologists rarely have an answer for. Late radiation injury — chronic tissue breakdown, non-healing wounds, osteoradionecrosis, radiation proctitis — affects up to 10% of cancer survivors. The mechanism is obliterative endarteritis: radiation permanently destroys the microvasculature of the tissue in its field. The result is chronically hypoxic tissue that cannot heal, cannot respond to surgery, and does not improve with time. Standard medicine has no pathway to rebuild what radiation destroyed. Hyperbaric Oxygen Therapy does. Under pressure, oxygen dissolves into plasma at concentrations 10–15x normal — reaching hypovascular tissue through diffusion rather than circulation. HBOT also stimulates angiogenesis: the formation of new blood vessels in radiation-damaged tissue. This is the only known intervention that addresses the underlying biology of late radiation injury rather than managing its symptoms. FDA-recognised indication. UHMS-endorsed protocol. Evidence from RCTs and multi-centre data. We've published a detailed clinical evidence breakdown for oncology teams, survivorship care providers, and cancer support centres. 🔗 https://hbotlab.com/hbot-cancer-survivors-radiation-evidence/ If you work in oncology, survivorship care, or rehabilitation — this is worth 10 minutes of your time. #HyperbaricOxygenTherapy #CancerSurvivorCare #RadiationInjury #Oncology #HBOT #SurvivorshipCare #HyperbaricMedicine #LateEffects #CancerRehabilitation #HBOTLAB #EvidenceBasedMedicine #Osteoradionecrosis #RadiationProctitis #CancerSupport

What Is the Future of Brachytherapy Afterloaders? Growth Forecasts According to a newly published market research report by 24LifeSciences, global brachytherapy afterloaders market was valued at USD 92.2 million in 2024 and is projected to reach USD 102 million by 2031, growing at a compound annual growth rate (CAGR) of 1.5% during the forecast period 2025-2031. A brachytherapy afterloader is a sophisticated medical device used to deliver targeted internal radiation therapy for cancer treatment. These systems are the technological backbone of modern brachytherapy, automating the precise placement and removal of radioactive sources directly inside or next to tumors. This targeted approach minimizes radiation exposure to healthy surrounding tissues and medical staff while delivering highly concentrated radiation doses to cancerous cells. These devices are critically important in treating prostate, gynecological, breast, and other cancers where precise radiation delivery is essential for optimal patient outcomes. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6426/brachytherapy-afterloaders-market-market-market

How Immunotherapy Drives Brain Tumor Therapeutics Market Growth According to a newly published market research report by 24LifeSciences, global brain tumor therapeutics market was valued at USD 1.27 billion in 2025 and is projected to grow from USD 1.41 billion in 2025 to reach USD 2.63 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.3% during the forecast period. Brain tumor therapeutics encompass a comprehensive range of treatments, including surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy, all designed to address abnormal cellular growth within the brain. These therapeutic modalities are critical for removing or destroying tumor cells, controlling their proliferation, and managing debilitating symptoms. The choice of treatment strategy is highly individualized, often involving a tailored combination of these approaches based on the specific tumor type, its grade and location, and the patient's overall health status. While surgical intervention remains a foundational element for many primary brain tumors, the ongoing development of novel targeted agents and sophisticated immunotherapies is actively revolutionizing the treatment landscape, offering renewed hope for patients confronting aggressive and recurrent tumor types. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8975/brain-tumor-therapeutics-market